Retatrutide (LY3437943) is an investigational triple-receptor GLP peptide targeting GLP-1, GIP, and glucagon — and the most-researched compound of its kind. This is our complete research library: independent, education-first, and compliance-framed for research use.
99%+ purity, third-party tested. Take the 60-second quiz for a personalized recommendation and 35% off.
For research and educational use only. Not medical advice; not for human consumption. Retatrutide is investigational and not FDA-approved.
